🇺🇸 FDA
Patent

US 11299546

FLT3-specific chimeric antigen receptors and methods using same

granted A61KA61K2039/505A61K2239/31

Quick answer

US patent 11299546 (FLT3-specific chimeric antigen receptors and methods using same) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Apr 12 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K2239/48